What we are studying
You are invited to join voluntarily in a clinical research study to find out if the investigational drug INCB024360 is safe and has beneficial effects when given with nivolumab in people who have advanced or metastatic solid tumors or certain tumor types. INCB024360 and nivolumab are both treatments designed to help your immune system (the part of your body that fights infections and cancer). By making your immune system more active, we hope to help your body fight your cancer. These drugs both help your immune system but they work in different ways. INCB024360 is a chemical drug that stops a protein (also called an enzyme) in your body called indoleamine-2,3-dioxygenase-1 (IDO1). This protein plays a role in blocking your immune system. Nivolumab is a monoclonal antibody, which is called a biological drug. Monoclonal antibodies are large proteins made by your body or they can be artificially created in a laboratory. Nivolumab is artificially created. It binds to and blocks a protein in your body called Programmed cell death protein 1 (PD-1). Blocking both IDO1 and PD-1 may help the body’s immune system fight your cancer. We hope these treatments result in the cancer shrinking and the person being treated living longer.
Subjects will be reimbursed a minor predetermined amount for travel expenses based on the result of budget negotiations with the Sponsor.